Acorda Therapeutics Inc expected to post a loss of $2.54 a share - Earnings Preview

Acorda Therapeutics

30/04/2021 12:03

* Acorda Therapeutics Inc  ACOR.OQ   ACOR.O  is expected to show
a fall in quarterly revenue when it reports results on May 6.
* The Ardsley, New York-based company is expected to report  a
21.2% decrease in revenue to $22.149 million from $28.1 million
a year ago, according to the estimate from one analyst, based on
Refinitiv data.​​
​* Refinitiv's mean analyst estimate for Acorda Therapeutics Inc
is for a loss of $2.54 per share. For the same quarter last
year, the company reported a loss of $3.06 per share.
* The current average analyst rating on the shares is "hold" and
the breakdown of recommendations is no "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts had risen by
about 26.0% in the last three months.​
* Wall Street's median 12-month price target for Acorda
Therapeutics Inc is $17.5​, about 72.2% above​ its last closing
price of $4.86. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Dec. 31 2020  -1.48       -1.48      -2.50     Missed  -68.9
 Sep. 30 2020  -1.79       -1.78      -1.38     Beat    22.5
 Jun. 30 2020  -2.89       -2.88      -2.10     Beat    27​
 Mar. 31 2020  -2.06       -2.49      -3.06     Missed  -23
 Dec.          -2.76​      -2.43      -0.90     Beat    63​
 31​ 2019​                                              
 Sep. 30 2019  -3.07       -3.07      -2.76     Beat    10.1​
 Jun. 30 2019  -6.38       -6.34      -3.30     Beat    48
 Mar. 31 2019  -5.70       -5.62      -3.36     Beat    40.3
 This summary was machine generated April 30 at 11:03 GMT.  All
figures in US dollars unless otherwise stated